The treatment pipeline for Friedreich’s ataxia is in a critical phase of development. There are clinical trials in process and more to become available by the end of 2021 and into 2022. All these studies are important as we need multiple treatments to address the symptoms and unmet medical need for individuals with FA.
Enrollment, participation, and completion of a clinical trial is an important commitment and a personal decision. Individuals who participate in a trial or research study are not only making a decision that can impact their own personal health, but also impact the whole FA community. We need individuals to voluntarily enroll and participate, to adhere to the study protocol, and to complete the study and final visits. Studies that fail or have inconclusive results due to lack of participation, lack of compliance, or high dropout rates, slows our progress towards treatments and a cure for FA.
When participants withdraw from a clinical trial due to travel fatigue to adhere to the clinical trial protocol, concern of being on placebo, or desiring to enroll in a different study, there is significant risk that the clinical trial will not reach conclusive results or meet its endpoint to determine safety and efficacy of the drug. Our persistence and dedication to research and advancing treatments for FA are bringing our community several choices of investigational studies with several more on the horizon. Please consider your personal situation and upcoming life events, along with the risks and benefits and goals of the trial or research study when enrolling in a clinical trial. Properly conducted and completed research studies deliver results we can have confidence in and will change the future for those diagnosed and living with FA.
Jen Farmer, Chief Executive Officer
Monthly Update - August 2021
- Category: News & Press Releases